Immuneering Corporation (IMRX)
| Market Cap | 326.37M |
| Revenue (ttm) | 2.56M |
| Net Income (ttm) | -28.59M |
| Shares Out | 26.32M |
| EPS (ttm) | -3.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,750 |
| Open | 13.11 |
| Previous Close | 13.00 |
| Day's Range | 12.33 - 14.19 |
| 52-Week Range | 12.23 - 33.99 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 39.25 (+216.5%) |
| Earnings Date | n/a |
About IMRX
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. We have more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, we developed a disease-agnostic platform that enables us to utilize human ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Immuneering stock is "Buy." The 12-month stock price forecast is 39.25, which is an increase of 216.53% from the latest price.
News
Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.
Industry Executive Brings More than 20 Years of Clinical Drug Development Expertise Industry Executive Brings More than 20 Years of Clinical Drug Development Expertise
Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External...
Preclinical Data Suggest IMM-1-104 May Offer Unique Therapeutic Advantage Compared with Binimetinib in NRAS Mutant Tumors
Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that a...
Immuneering Added to the Nasdaq Biotechnology Index
CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that a...
Immuneering Announces Participation in December Investor Conferences
Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells Highlighting proprietary ...
Immuneering to Participate in Jefferies 2021 London Healthcare Conference
To highlight proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells To highlight proprietary ...
Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights
Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024
Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular ...
Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with Sotoras...
Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Confe...
Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition
Immuneering Announces Inclusion in the Russell 2000® Index
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that ...
5 Stocks With High Insider Buys Over Past 2 Months
According to the Insider Cluster Buys page, a Premium feature of GuruFocus, five stocks with high insider buys over the past two months are Orange County Bancorp Inc. ( OBT , Financial), FS KKR Capital ...
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates
Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024
Immuneering to Participate in September Investor Conferences
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that ...
Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to ...
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that a...
Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO
Immuneering Corp (NASDAQ: IMRX) has kept a relatively low profile since launching with $17 million back in 2019. That is until it landed another $62 million and recruited Jefferies analyst Biren Amin as...
Immuneering Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that a...